Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Wins Medi-Cal Coverage for OVA1

NEW YORK (GenomeWeb) – Vermillion said today that Medi-Cal, California's Medicaid program, now supports the company's OVA1 ovarian cancer test in its medical policy guidelines.

According to Vermillion, Medi-Cal covers more than 12.6 million lives, or roughly a third of the covered lives in California.

OVA1 measures levels of five proteins in patient blood and is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.